SeptiCyte® was developed to empower clinicians to provide the most effective treatment, by using biomarkers in the patient’s immune system to measure host response signals that indicate sepsis.
In About An Hour
BARDA Awards Contract to Immunexpress to Support the Clinical Validation of SeptiCyte® RAPID for the Triage of COVID-19 Patients
Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte® RAPID
We Use the Patient’s Immune System to Unlock a Rapid and Accurate Sepsis Diagnosis
SeptiCyte®RAPID revolutionizes sepsis diagnosis and treatment, with actionable results available in an hour. SeptiCyte®RAPID can determine the likelihood of sepsis and differentiate from non-infectious systemic inflammatory response syndrome (SIRS) in critically ill patients. The test, which uses a small volume of blood, can be performed easily in any hospital lab with the Biocartis Idylla™ molecular testing system.
Why SeptiCyte® RAPID for Sepsis Diagnosis
Sepsis can escalate quickly and fatally. Until now, blood tests for sepsis have been unreliable and slow. For hospitals in the U.S., sepsis treatment now represents the highest total in-patient cost. By knowing whether sepsis is present, clinicians can initiate the most appropriate treatment as quickly as possible, including ICU admission when needed.
Sepsis can be a killer, resulting in organ failure and death. The overuse of antibiotics can lead to greater antibiotic resistance among vulnerable patient populations. An early sepsis diagnosis can make the difference between life and death.